Q4 2025 Elite Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Elite Pharmaceuticals Inc (ELTP) reported a significant revenue increase of 52% for the fiscal year 2025, reaching $84 million compared to $56.6 million in the previous year.
- The company successfully launched its Lisdexamfetamine product line, capturing a decent market share in a highly competitive market.
- Operating income nearly doubled, increasing by 82% to $19.6 million from $10.8 million in the previous fiscal year.
- The company's balance sheet continues to strengthen with a 41% increase in working capital, reaching $45.9 million.
- Elite Pharmaceuticals Inc (ELTP) has low and decreasing debt, which is a hallmark of a strong financial position.
- The Lisdexamfetamine market remains highly competitive with over 10 suppliers, leading to price and quota pressures.
- Despite increased revenues, the company reported a pre-tax loss of $52,000 due to a non-cash expense related to the change in fair value of derivatives.
- Earnings per share (EPS) dropped to zero from $0.02 in the previous year, impacted by non-cash items.
- The company faces challenges in expanding its manufacturing capacity beyond tablets and capsules, as highlighted by inquiries about ketamine production.
- Elite Pharmaceuticals Inc (ELTP) has not yet hired an M&A firm for potential mergers or acquisitions, indicating uncertainty in strategic growth plans.
Good morning, ladies and gentlemen. Welcome to the Elite Pharmaceuticals' conference call.
(Operator Instructions) Before management begins speaking, the conference has the following statement: Elite would like to remind the listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties that are subject to change at any time, including, but not limited to, statements about Elite's expectations regarding forward-operating results.
Forward-looking statements are made pursuant to the Safe Harbor Provisions of the Federal Securities Laws and represent management's current expectations. Actual results may differ materially. Elite disclaims any obligation to update or revise its forward-looking statements, except as required by law.
More complete information regarding forward-looking statements, risks, and uncertainties can be found in the reports Elite files with the SEC, which is available on Elite's website at elitepharma.com under the Investor Relations section. Elite encourages you to review these documents carefully.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
